Guides and explainers on Retatrutide — mechanism of action, dosage and concentrations, compound comparisons, storage and reconstitution, clinical research, and Australian access. All material is research-use only.
What is Retatrutide? An explainer on the GLP-1/GIP/glucagon triple receptor agonist — mechanism, receptor targets, and how it differs from Tirzepatide.
ResearchRetatrutide vs Tirzepatide — receptor profiles, structural differences and relative potency for research applications. A comparison for researchers.
ResearchA research-lab guide to reconstituting lyophilised peptides — bacteriostatic vs sterile water, technique, storage, and stability windows.
ResearchA complete Retatrutide research guide — dosage variants (10mg–60mg), storage before and after reconstitution, and procurement considerations.
ResearchHow Retatrutide works: a research explainer on triple GLP-1, GIP and glucagon receptor agonism, the LY3437943 structure, and combined metabolic effects.
ResearchRetatrutide vs Semaglutide compared for research: triple GIP/GLP-1/glucagon agonism versus single GLP-1 agonism, mechanisms, and clinical trial data.
ResearchA research review of Retatrutide weight loss data: Phase 2 NEJM findings, Phase 3 TRIUMPH outcomes, and the metabolic mechanisms studied behind them.
ResearchRetatrutide in Australia for research: the TGA regulatory context, what research-use-only means, and how Australian laboratories source verified peptides.
ResearchA research guide to Retatrutide dosage: clinical trial dose ranges, vial configurations from 10mg to 60mg, and how to calculate laboratory concentrations.
ResearchA research profile of the Retatrutide peptide: why purity matters in vitro, what HPLC over 99% means, lyophilised form, storage, and COA documentation.
ResearchA laboratory guide to Retatrutide storage and reconstitution: temperatures, sterile technique, concentration maths, aliquoting, and degradation signs.
ResearchThe science of GLP-1, GIP and glucagon triple agonists: incretin background, single vs dual vs triple agonism, and why metabolic researchers study them.
ResearchA research summary of Retatrutide Phase 3 results from the TRIUMPH and TRANSCEND programmes — weight and metabolic endpoints from Eli Lilly trials.
ResearchRetatrutide vs Tirzepatide compared for research: triple GIP/GLP-1/glucagon agonism versus dual GIP/GLP-1, the extra glucagon axis, and trial data.
HPLC-verified Retatrutide with a Certificate of Analysis on every tested batch. Secure checkout in AUD.
View Retatrutide →